Prosensa receives �7.5m milestone payment as part of its program with GlaxoSmithKline in Duchenne Muscular Dystrophy - Prosensa

Prosensa receives �7.5m milestone payment as part of its program with GlaxoSmithKline in Duchenne Muscular Dystrophy - Prosensa: "GSK2402968 (PRO051) is an investigational antisense oligonucleotide which induces exon�skipping of exon 51. The six-month data from the open label Phase IIa extension study in 12�patients with DMD, receiving a weekly 6mg/kg systemic delivery by subcutaneous injection, will�be presented at the 15th International Congress of the World Muscle Society in Japan, October�12-16. The data will be presented by Dr. Nathalie Goemans, MD, from the Department of�Pediatric Neurology, University of Leuven, Belgium."